RANGER?
Report
- Report Number
- 2124215-2022-43198
- Event Type
- Injury
- Date Received
- October 28, 2022
- Date of Event
- September 29, 2022
- Report Date
- June 30, 2025
- Manufacturer
- BOSTON SCIENTIFIC CORPORATION
- Product Code
- ONU
- UDI-DI
- 08714729976103
- PMA / PMN Number
- P190019
- Adverse Event
- Yes
- Report Source
- Manufacturer report
- Reporter Location
- NY, US
- Reporter Occupation
- PHYSICIAN
- Health Professional
- Yes
Narratives
PATIENT IDENTIFIER: (B)(6).
UPDATED FIELDS: B5 - DESCRIBE EVENT OR PROBLEM. D1 - BRAND NAME. D4 - UNIQUE IDENTIFIER (UDI) #. H6 - IMPACT CODES.
ELEGANCE CLINICAL STUDY. IT WAS REPORTED THAT RESTENOSIS OCCURRED 322 DAYS POST INDEX PROCEDURE WITH THE RANGER (DCB). THE SUBJECT UNDERWENT TREATMENT WITH THE RANGER DRUG-COATED BALLOON ON 11-NOV-2021 AS A PART OF THE ELEGANCE CLINICAL TRIAL. THE TARGET LESION WAS IN THE RIGHT MID SUPERFICIAL FEMORAL ARTERY (SFA) WITH 6.00 MM PROXIMAL REFERENCE VESSEL DIAMETER AND 6.00 MM DISTAL REFERENCE VESSEL DIAMETER WITH LESION LENGTH OF 60 MM WITH 80% STENOSIS. PRIOR TO TARGET LESION TREATMENT WITH THE STUDY DEVICE, PRE-DILATION WAS PERFORMED USING 5.0 MM X 40 MM STERLING PTA BALLOON. THE TREATMENT OF TARGET LESION WAS PERFORMED BY DILATATION USING STUDY DEVICE 6 MM X 60 MM, RANGER DRUG COATED BALLOON. FOLLOWING POST DILATATION, THE FINAL RESIDUAL STENOSIS WAS NOTED TO BE 5%. ON (B)(6) 2022, THE SUBJECT VISITED THE HOSPITAL WITH SYMPTOMS RELATED TO RIGHT LEG CLAUDICATION WITH RIGHT GREATER THAN LEFT AND PRIOR RIGHT PARTIAL GREAT TOE AND SECOND TOE COMPLETE AMPUTATION. ON THE SAME DAY, THE SUBJECT UNDERWENT LOWER EXTREMITY ANGIOGRAPHY WHICH REVEALED SEVERE BILATERAL SFA STENOSIS. ON (B)(6) 2022, 322 DAYS POST INDEX PROCEDURE, 70% STENOSIS NOTED IN THE RIGHT MID SUPERFICIAL FEMORAL ARTERY WAS REVASCULARIZED BY BALLOON ANGIOPLASTY USING 5 MM X 40 MM MUSTANG BALLOON FOLLOWED BY REPEATED BALLOON ANGIOPLASTIES USING DRUG COATED BALLOONS AND PLACEMENT OF 6 MM X 120 MM ELUVIA DRUG ELUTING STENT. POST DILATATION WITH 6 MM X 100 MM MUSTANG BALLOON, THE FINAL RESIDUAL STENOSIS WAS NOTED TO BE 1%. ON THE SAME DAY, THE EVENT WAS CONSIDERED RESOLVED.
IT WAS REPORTED THAT RESTENOSIS OCCURRED 322 DAYS POST INDEX PROCEDURE WITH THE RANGER (DCB). THE SUBJECT UNDERWENT TREATMENT WITH THE RANGER DRUG-COATED BALLOON ON (B)(6) 2021 AS A PART OF THE ELEGANCE CLINICAL TRIAL. THE TARGET LESION WAS IN THE RIGHT MID SUPERFICIAL FEMORAL ARTERY (SFA) WITH 6.00 MM PROXIMAL REFERENCE VESSEL DIAMETER AND 6.00 MM DISTAL REFERENCE VESSEL DIAMETER WITH LESION LENGTH OF 60 MM WITH 80% STENOSIS. PRIOR TO TARGET LESION TREATMENT WITH THE STUDY DEVICE, PRE-DILATION WAS PERFORMED USING 5.0 MM X 40 MM STERLING PTA BALLOON. THE TREATMENT OF TARGET LESION WAS PERFORMED BY DILATATION USING STUDY DEVICE 6 MM X 60 MM, RANGER DRUG COATED BALLOON. FOLLOWING POST DILATATION, THE FINAL RESIDUAL STENOSIS WAS NOTED TO BE 5%. ON (B)(6) 2022, THE SUBJECT VISITED THE HOSPITAL WITH SYMPTOMS RELATED TO RIGHT LEG CLAUDICATION WITH RIGHT GREATER THAN LEFT AND PRIOR RIGHT PARTIAL GREAT TOE AND SECOND TOE COMPLETE AMPUTATION. ON THE SAME DAY, THE SUBJECT UNDERWENT LOWER EXTREMITY ANGIOGRAPHY WHICH REVEALED SEVERE BILATERAL SFA STENOSIS. ON (B)(6) 2022, 322 DAYS POST INDEX PROCEDURE, 70% STENOSIS NOTED IN THE RIGHT MID SUPERFICIAL FEMORAL ARTERY WAS REVASCULARIZED BY BALLOON ANGIOPLASTY USING 5 MM X 40 MM MUSTANG BALLOON FOLLOWED BY REPEATED BALLOON ANGIOPLASTIES USING DRUG COATED BALLOONS AND PLACEMENT OF 6 MM X 120 MM ELUVIA DRUG ELUTING STENT. POST DILATATION WITH 6 MM X 100 MM MUSTANG BALLOON, THE FINAL RESIDUAL STENOSIS WAS NOTED TO BE 1%. ON THE SAME DAY, THE EVENT WAS CONSIDERED RESOLVED. IT WAS FURTHER REPORTED THAT THE RESTENOSIS WAS DIAGNOSED ON (B)(6) 2022, PREVIOUSLY REPORTED TO HAVE BEEN DIAGNOSED ON (B)(6) 2022. ON (B)(6) 2022, THE SUBJECT VISITED THE HOSPITAL FOR 6 MONTH FOLLOW UP VISIT AND UNDERWENT ARTERIAL DUPLEX OF THE TARGET LIMB (RIGHT LEG) WHICH REVEALED MODERATE ATHEROSCLEROSIS WITH 50-75% STENOSIS IN THE PROXIMAL, MID SUPERFICIAL FEMORAL ARTERY AND PROFUNDA FEMORIS ARTERY, 75-90% STENOSIS IN THE PROXIMAL POSTERIOR TIBIAL ARTERY, AND A TOTAL OCCLUSION OF THE MID POSTERIOR TIBIAL ARTERY. ON (B)(6) 2022, THE SUBJECT VISITED THE HOSPITAL WITH COMPLAINTS OF WORSENING BILATERAL LOWER EXTREMITY CLAUDICATION, WITH SYMPTOMS IN THE RIGHT GREATER THAN THE LEFT. PHYSICAL EXAMINATION REVEALED LEFT LOWER EXTREMITY EDEMA, PALPABLE DP PULSES BILATERALLY. IN RESPONSE, THE SUBJECT WAS RECOMMENDED FOR PERIPHERAL ANGIOGRAM WITH POSSIBLE INTERVENTION. LOWER EXTREMITY ANGIOGRAPHY PERFORMED THE SAME DAY ALSO REVEALED PATENT PERONEAL ARTERY, OCCLUSION IN THE ANTERIOR TIBIAL ARTERY WHICH RECONSTITUTES ABOVE THE ANKLE BY COLLATERALS FROM THE PERONEAL ARTERY, AND OCCLUSION IN THE TIBIO-PERONEAL TRUNK AND POSTERIOR TIBIAL ARTERY. 70% STENOSIS NOTED IN THE RIGHT PROXIMAL SFA, MID SFA, AND DISTAL SFA WAS TREATED BY PRE-DILATION USING 5 MM X 40 MM MUSTANG BALLOON FOLLOWED BY DILATION USING 6.0 MM X 60 MM AND 6.0 MM X 100 MM NON-BOSTON SCIENTIFIC DRUG COATED BALLOONS AND . SUBSEQUENTLY, ANGIOGRAPHY REVEALED FLOW LIMITING DISSECTION DUE TO THE 6.0 MM X 100 MM NON-BOSTON SCIENTIFIC DRUG COATED BALLOON, WHICH WAS TREATED BY PLACEMENT OF A 6.0 MM X 120 MM ELUVIA DRUG ELUTING STENT. POST DILATATION, USING 6 MM X 100 MM MUSTANG BALLOON, THE FINAL RESIDUAL STENOSIS WAS NOTED TO BE 1% (001/TLR). ON THE SAME DAY, THE EVENT WAS CONSIDERED TO BE RESOLVED AND THE SUBJECT WAS DISCHARGED FROM THE HOSPITAL ON DUAL ANTIPLATELET THERAPY.
Devices
| Seq | Brand | Generic | Product Code | Manufacturer | Model | Lot | UDI-DI |
|---|---|---|---|---|---|---|---|
| 2835616 | RANGER? | DRUG-ELUTING PERIPHERAL TRANSLUMINAL ANGIOPLASTY CATHETER | ONU | BOSTON SCIENTIFIC CORPORATION | H74939419600610 | 0027452976 | 08714729976103 |
Patients
| Seq | Age | Sex | Outcome | Treatment |
|---|---|---|---|---|
| 1 | 65 YR | Male | Hospitalization| R |